Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Perioperative Versus Adjuvant FOLFIRINOX for Resectable Pancreatic Cancer: the PREOPANC-3 Study

NCT04927780 is registered in ClinicalTrials.gov with Erasmus Medical Center as lead sponsor.

NCT NCT04927780
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04927780 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Perioperative Versus Adjuvant FOLFIRINOX for Resectable Pancreatic Cancer: the PREOPANC-3 Study
Lead sponsor
Erasmus Medical Center
Phase
Phase 3
Overall status
Active, not recruiting
Start date
September 7, 2021
Completion date
July 31, 2029
Enrollment
378 (estimated)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic cancer, pancreatic ductal adenocarcinoma, resectable pancreatic adenocarcinoma